|
gptkbp:instanceOf
|
gptkb:cancer
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:cellType
|
T lymphocyte
|
|
gptkbp:countryOfOperation
|
gptkb:China
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
gptkb:Novartis
gptkb:Bristol_Myers_Squibb
gptkb:Legend_Biotech
|
|
gptkbp:firstApprovedProduct
|
gptkb:Kymriah
gptkb:Yescarta
|
|
gptkbp:fullName
|
gptkb:Chimeric_Antigen_Receptor_T-cell_therapies
|
|
gptkbp:futureDirection
|
allogeneic CAR-T
improved safety profiles
targeting solid tumors
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CAR-T cell therapies
|
|
gptkbp:limitation
|
high cost
complex manufacturing
limited efficacy in solid tumors
|
|
gptkbp:mechanismOfAction
|
genetically engineered T cells to express chimeric antigen receptors
|
|
gptkbp:monitors
|
hospitalization
ICU care (in severe cases)
|
|
gptkbp:processor
|
genetic modification
cell expansion
cell infusion
leukapheresis
lymphodepleting chemotherapy
|
|
gptkbp:relatedTo
|
gptkb:Axicabtagene_ciloleucel
gptkb:Brexucabtagene_autoleucel
gptkb:Ciltacabtagene_autoleucel
gptkb:Idecabtagene_vicleucel
gptkb:Tisagenlecleucel
|
|
gptkbp:researchArea
|
multiple myeloma
solid tumors
|
|
gptkbp:riskFactor
|
infection
B-cell aplasia
|
|
gptkbp:sideEffect
|
neurotoxicity
cytokine release syndrome
|
|
gptkbp:target
|
gptkb:CD19
gptkb:BCMA
|
|
gptkbp:treatment
|
personalized medicine
|
|
gptkbp:type
|
autologous cell therapy
|
|
gptkbp:usedFor
|
leukemia
B-cell lymphoma
hematologic malignancies
|
|
gptkbp:bfsParent
|
gptkb:Caribou_Biosciences
|
|
gptkbp:bfsLayer
|
5
|